At a record breaking ESC 2025 in Madrid, Spain (29 August-1 September 2025), with over 1,100 sessions showcasing practice-changing research, Lp(a) focused advances included new ESC/EAS guidance on Lp(a) as a cardiovascular risk-enhancing factor, together with new research on reduced need for lipoprotein apheresis with Lp(a) lowering therapy, latest trends in Lp(a) testing, patient advice about Lp(a), and further evidence linking elevated Lp(a) with poor cardiovascular outcomes.
- ESC/EAS adds Lp(a) recommendation in new dyslipidaemia focused update
- Pelacarsen reduces need for lipoprotein apheresis
- Norway has one of highest Lp(a) testing rates
- Variable availability of Lp(a) testing in Australia
- Patients need more information about Lp(a)
- Elevated Lp(a) linked to lower event free survival
Reporting by Jenny Bryan, Managing Editor
